4-[(3-methylphenyl)thio]pyridine | 646511-40-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-[(3-methylphenyl)thio]pyridine
• 英文别名: Pyridine, 4-[(3-methylphenyl)thio]-；4-(3-methylphenyl)sulfanylpyridine
• CAS: 646511-40-2
• 化学式: C₁₂H₁₁NS
• 分子量: 201.292
• InChiKey: MIBCHYIMODVJPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-氯吡啶 、 3-甲基苯硫酚 在 potassium tert-butylate 作用下， 以 异丙醇 为溶剂， 以53%的产率得到4-[(3-methylphenyl)thio]pyridine
  参考文献：
  名称：

  Antimycobacterial Agents. 1. Thio Analogues of Purine

  摘要：

  Thio analogues of purine, pyridine, and pyrimidine were prepared based on the initial activity screening of several analogues of these heterocycles against Mycobacterium tuberculosis (Mtb). Certain 6-thio-substituted purine analogues described herein showed moderate to good inhibitory activity. In particular, two purine analogues 9-(ethylcarboxymethyl)-6-(decylthio)9H-purine (20) and 9-(ethylcarboxymethyl)-6-(dodecylthio)-9H-purine (21) exhibited MIC values of 1.56 and 0.78 mug/mL respectively against the Mtb H(37)Rv strain. N-9-Substitution apparently enhances the antimycobacterial activity in the purine series described herein.

  DOI：

  10.1021/jm030389b

文献信息

• INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
  申请人：Dumas Jacques

  公开号：US20120046290A1

  公开（公告）日：2012-02-23

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

  本发明涉及一组芳香脲在治疗细胞因子介导的疾病（除癌症外）和蛋白水解酶介导的疾病（除癌症外）中的用途，以及用于此类治疗的药物组合物。
• Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
  申请人：Miller Scott

  公开号：US20080269265A1

  公开（公告）日：2008-10-30

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS
  申请人：Dumas Jacques

  公开号：US20070244120A1

  公开（公告）日：2007-10-18

  Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

  治疗由raf激酶介导的肿瘤的方法，包括使用取代脲化合物，以及这些化合物本身。
• Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas
  申请人：Dumas Jacques

  公开号：US20080194580A1

  公开（公告）日：2008-08-14

  This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.

  本发明涉及一组喹啉基、异喹啉基和吡啶基脲类化合物，它们的用途是治疗raf介导的疾病，并且包含这些脲类化合物的制药组合物用于此类治疗。
• INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
  申请人：Miller Scott

  公开号：US20090093526A1

  公开（公告）日：2009-04-09

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

  本发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的制药组合物。